



16 December 2025
EMA/394227/2025 **Corr 1**¹
Human Medicines Division

Overview of (invented) names reviewed in November 2025 by the Name Review Group (NRG)

Adopted at the CHMP meeting of 11 December 2025

	NRG meeting 11-12 February		NRG meeting 8-9 April		NRG meeting 11-12 June		NRG meeting 23-24 September		NRG meeting 18-19 November		2025 total	
	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected	Accepted	Rejected
Proposed (invented) names	47	38	56	35	31	33	56	45	83	39	273	190
Proposed INN+MAH/TM names	1	0	1	0	2	0	2	0	8	0	14	0
Re-use/re-confirmation applications	2	0	0	0	3	1	0	0	4	0	9	1
Justification for retention of (invented) name *	3	3	4	0	1	5	2	6	4	2	14	16

*In case of objections to the proposed (invented) name(s), the applicant may justify the retention of the proposed invented name using the relevant justification form available on the EMA website.

¹ This revision concerns correction of the numbers of objections raised during November 2025 meeting, as well as the total numbers of objections raised in year 2025.



	NRG meeting 11-12 February		NRG meeting 8-9 April		NRG meeting 11-12 June		NRG meeting 23-24 September		NRG meeting 18-19 November		2025 total	
	Endorsed	Not endorsed	Endorsed	Not endorsed	Endorsed	Not endorsed	Endorsed	Not endorsed	Endorsed	Not endorsed	Endorsed	Not endorsed
Total number of objections raised	78	163	65	139	72	139	94	170	73	170	382	781
Similarity with other (invented) name	49	143	48	113	46	113	62	135	55	142	260	646
Conveys misleading therapeutic connotations	4	2	0	0	1	1	2	4	0	0	7	7
Conveys misleading pharmaceutical connotations	0	0	0	0	0	0	0	0	1	0	1	0
Similarity with INN	5	8	9	11	15	12	10	7	7	13	46	51
Inclusion of INN stem	1	1	0	0	0	0	1	0	0	0	2	1
Unacceptable qualifiers	1	1	0	0	0	0	0	0	0	0	1	1
Conveys a promotional message	8	4	1	8	4	3	5	15	4	12	22	42
Appears offensive or has an inappropriate connotation	0	0	4	1	3	0	2	0	4	0	13	1
Similarity between name of individual active substance and fixed combinations and/or between fixed combinations	0	0	0	0	0	0	0	0	0	0	0	0
Similarity between name of prodrug and related active substance	0	0	0	0	0	0	0	0	0	0	0	0
Inclusion of common umbrella segment	0	0	0	0	0	0	0	0	0	0	0	0
Potential difficulties in pronunciation	6	1	3	1	2	3	7	1	0	1	18	7
Others	0	0	0	0	2	2	2	3	2	2	6	7

See [Guideline on the acceptability of names for human medicinal products processed through the centralised procedure \(EMA/CHMP/287710/2014 - Rev. 7\)](#) for detailed explanations of criteria used.